Cancer clinical trials in the region Auvergne-Rhône-Alpes
277 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
#NCT06236438
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Metastatic
None
Systemic Treatment-Naive
ALK
EGFR
Centre Hospitalier Universitaire de Grenoble (La Tronche)
Abbvie
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
Phase 3
Lymphoma
CLL & Richter's syndrome
#NCT06428019
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Lymphocytic lymphoma
> 60 ml/min
50-60 ml/min
30-50 ml/min
Systemic Treatment-Naive
Institut de Cancérologie et d’Hématologie Universitaire de Saint-Étienne (CHU Saint-Étienne) (Saint-Priest-en-Jarez), Centre Hospitalier Métropole Savoie (Chambéry)
Abbvie
Phase 3
CLL & Richter's syndrome
#NCT05947851
CLL (Chronic Lymphocytic Leukemia)
None
Treated / Controled
1
2
3 or more
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
None
Systemic Treatment-Naive
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite)
Daiichi Sankyo